CN115484981A - 用于调节免疫应答的材料和方法 - Google Patents

用于调节免疫应答的材料和方法 Download PDF

Info

Publication number
CN115484981A
CN115484981A CN202180031394.5A CN202180031394A CN115484981A CN 115484981 A CN115484981 A CN 115484981A CN 202180031394 A CN202180031394 A CN 202180031394A CN 115484981 A CN115484981 A CN 115484981A
Authority
CN
China
Prior art keywords
amino acid
cdr2
cdr3
antibody
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180031394.5A
Other languages
English (en)
Chinese (zh)
Inventor
R·甘尼桑
I·S·格鲁瓦尔
S·辛格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/031749 external-priority patent/WO2020227457A1/en
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CN115484981A publication Critical patent/CN115484981A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202180031394.5A 2020-02-27 2021-02-26 用于调节免疫应答的材料和方法 Pending CN115484981A (zh)

Applications Claiming Priority (91)

Application Number Priority Date Filing Date Title
US202062982462P 2020-02-27 2020-02-27
US202062982664P 2020-02-27 2020-02-27
US202062982469P 2020-02-27 2020-02-27
US202062982602P 2020-02-27 2020-02-27
US202062982492P 2020-02-27 2020-02-27
US202062982574P 2020-02-27 2020-02-27
US202062982374P 2020-02-27 2020-02-27
US202062982669P 2020-02-27 2020-02-27
US202062982525P 2020-02-27 2020-02-27
US202062982505P 2020-02-27 2020-02-27
US202062982591P 2020-02-27 2020-02-27
US202062982535P 2020-02-27 2020-02-27
US202062982548P 2020-02-27 2020-02-27
US202062982478P 2020-02-27 2020-02-27
US62/982462 2020-02-27
US62/982602 2020-02-27
US62/982469 2020-02-27
US62/982548 2020-02-27
US62/982535 2020-02-27
US62/982664 2020-02-27
US62/982591 2020-02-27
US62/982505 2020-02-27
US62/982492 2020-02-27
US62/982478 2020-02-27
US62/982525 2020-02-27
US62/982669 2020-02-27
US62/982374 2020-02-27
US62/982574 2020-02-27
US202062989010P 2020-03-13 2020-03-13
US202062989027P 2020-03-13 2020-03-13
US202062989042P 2020-03-13 2020-03-13
US202062989052P 2020-03-13 2020-03-13
US202062989075P 2020-03-13 2020-03-13
US202062989024P 2020-03-13 2020-03-13
US202062989045P 2020-03-13 2020-03-13
US202062989036P 2020-03-13 2020-03-13
US202062989002P 2020-03-13 2020-03-13
US202062989057P 2020-03-13 2020-03-13
US202062988996P 2020-03-13 2020-03-13
US202062989068P 2020-03-13 2020-03-13
US202062989006P 2020-03-13 2020-03-13
US202062989018P 2020-03-13 2020-03-13
US62/989010 2020-03-13
US62/989057 2020-03-13
US62/989006 2020-03-13
US62/989045 2020-03-13
US62/988996 2020-03-13
US62/989052 2020-03-13
US62/989075 2020-03-13
US62/989027 2020-03-13
US62/989068 2020-03-13
US62/989036 2020-03-13
US62/989042 2020-03-13
US62/989024 2020-03-13
US62/989018 2020-03-13
US62/989002 2020-03-13
PCT/US2020/031749 WO2020227457A1 (en) 2019-05-08 2020-05-07 Materials and methods for modulating t cell mediated immunity
USPCT/US2020/031749 2020-05-07
US202063074946P 2020-09-04 2020-09-04
US202063074839P 2020-09-04 2020-09-04
US202063074676P 2020-09-04 2020-09-04
US202063074655P 2020-09-04 2020-09-04
US202063074903P 2020-09-04 2020-09-04
US202063074749P 2020-09-04 2020-09-04
US202063074759P 2020-09-04 2020-09-04
US202063074854P 2020-09-04 2020-09-04
US202063074735P 2020-09-04 2020-09-04
US202063074893P 2020-09-04 2020-09-04
US202063074700P 2020-09-04 2020-09-04
US202063074962P 2020-09-04 2020-09-04
US202063074937P 2020-09-04 2020-09-04
US202063074925P 2020-09-04 2020-09-04
US63/074854 2020-09-04
US63/074903 2020-09-04
US63/074759 2020-09-04
US63/074676 2020-09-04
US63/074962 2020-09-04
US63/074700 2020-09-04
US63/074893 2020-09-04
US63/074735 2020-09-04
US63/074655 2020-09-04
US63/074925 2020-09-04
US63/074937 2020-09-04
US63/074749 2020-09-04
US63/074946 2020-09-04
US63/074839 2020-09-04
US202063112462P 2020-11-11 2020-11-11
US202063112475P 2020-11-11 2020-11-11
US63/112475 2020-11-11
US63/112462 2020-11-11
PCT/US2021/019766 WO2021173896A1 (en) 2020-02-27 2021-02-26 Materials and methods for modulating an immune response

Publications (1)

Publication Number Publication Date
CN115484981A true CN115484981A (zh) 2022-12-16

Family

ID=77492135

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180031394.5A Pending CN115484981A (zh) 2020-02-27 2021-02-26 用于调节免疫应答的材料和方法

Country Status (10)

Country Link
US (1) US20220306739A1 (https=)
JP (1) JP2023515199A (https=)
KR (1) KR20220147631A (https=)
CN (1) CN115484981A (https=)
AU (1) AU2021225870A1 (https=)
CA (1) CA3173268A1 (https=)
IL (1) IL295897A (https=)
MX (1) MX2022010664A (https=)
TW (1) TW202144415A (https=)
WO (1) WO2021173896A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501541B2 (en) 2015-01-27 2019-12-10 Lava Therapeutics B.V. Single domain antibodies targeting CD1d
AU2019344300A1 (en) 2018-09-19 2021-04-22 LAVA Therapeutics N.V. Dual acting CD1D immunoglobulin
MX2021010857A (es) 2019-03-11 2021-12-15 Janssen Biotech Inc Anticuerpos biespecificos anti-v(beta17)/anti-cd123.
MA55903A (fr) 2019-05-08 2022-03-16 Janssen Biotech Inc Matières et méthodes pour moduler l'immunité médiée par les lymphocytes t
CN115443150A (zh) 2019-12-17 2022-12-06 德克萨斯大学系统董事会 新型ddr1抗体和其用途
KR20230042035A (ko) 2020-07-08 2023-03-27 라바 테라퓨틱스 엔.브이. Psma와 감마-델타 t 세포 수용체에 결합할 수 있는 항체
WO2022056197A1 (en) 2020-09-11 2022-03-17 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
US20220089737A1 (en) * 2020-09-11 2022-03-24 Janssen Biotech, Inc. Multi-specific immune targeting molecules and uses thereof
TW202227495A (zh) 2020-09-11 2022-07-16 美商健生生物科技公司 用於調節β鏈介導之免疫的方法及組成物
EP4237003A4 (en) 2020-10-28 2025-07-09 Janssen Biotech Inc COMPOSITIONS AND METHODS FOR MODULATING GAMMA DELTA CHAIN-MEDIATED IMMUNITY
CN120076829A (zh) 2022-10-18 2025-05-30 明治制果药业株式会社 T细胞肿瘤的治疗剂
AU2023411024A1 (en) * 2022-12-23 2025-08-07 The Wistar Institute Of Anatomy And Biology Siglec 9 inhibitors and methods of use thereof for enhancing immunotherapy efficacy
TW202537974A (zh) * 2023-11-15 2025-10-01 大陸商上海盛迪醫藥有限公司 Ｔｒｇｖ９結合蛋白及其醫藥用途
WO2025220690A1 (ja) * 2024-04-17 2025-10-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Ｔ細胞腫瘍以外の悪性腫瘍患者に有効な二重特異性抗体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113966231A (zh) * 2019-05-08 2022-01-21 詹森生物科技公司 用于调节t细胞介导的免疫力的材料和方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002351208A1 (en) * 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
JP2012505654A (ja) * 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
DK3129404T3 (da) * 2014-04-10 2026-04-20 Lava Therapeutics N V Immunglobuliner, der binder humane vgamma9vdelta2-t-cellereceptorer
CA3297793A1 (en) * 2016-12-26 2026-03-02 Kagoshima University Antibody which binds to myelin oligodendrocyte glycoprotein
EP3743081A4 (en) * 2018-01-23 2021-12-01 New York University SPECIFIC ANTIBODIES OF THE DELTA 1 CHAIN OF THE T-LYMPHOCYTE RECEPTOR
JOP20190116A1 (ar) * 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
CA3101271A1 (en) * 2018-05-24 2019-11-28 Janssen Biotech, Inc. Anti-cd3 antibodies and uses thereof
JP2023517660A (ja) * 2020-03-13 2023-04-26 ヤンセン バイオテツク，インコーポレーテツド シグレック３／ｃｄ３３に結合させるための材料及び方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113966231A (zh) * 2019-05-08 2022-01-21 詹森生物科技公司 用于调节t细胞介导的免疫力的材料和方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HANS-HEINRICH OBERG: "Novel bispecific antibodies increaseγδT-cell cytotoxicity against pancreatic cancer cells", CANCER RES, vol. 74, no. 1, 1 March 2014 (2014-03-01), pages 1350 - 1355 *

Also Published As

Publication number Publication date
IL295897A (en) 2022-10-01
MX2022010664A (es) 2022-11-30
US20220306739A1 (en) 2022-09-29
JP2023515199A (ja) 2023-04-12
KR20220147631A (ko) 2022-11-03
WO2021173896A1 (en) 2021-09-02
AU2021225870A1 (en) 2022-10-20
WO2021173896A8 (en) 2022-10-06
TW202144415A (zh) 2021-12-01
CA3173268A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
CN115484981A (zh) 用于调节免疫应答的材料和方法
JP2021521784A (ja) ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用
US20240150464A1 (en) Materials and methods for modulating t cell mediated immunity
EP4228693A1 (en) Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii
US20210284731A1 (en) Methods and materials for modulating an immune response
US12492256B2 (en) Methods and compositions for modulating beta chain mediated immunity
US20260055185A1 (en) Materials and methods for modulating delta chain mediated immunity
WO2022056197A9 (en) Immune targeting molecules and uses thereof
CN116615456A (zh) 用于调节β链介导的免疫的方法和组合物
HK40085531A (en) Materials and methods for modulating an immune response
EP4110390A1 (en) Materials and methods for modulating an immune response
WO2026085173A1 (en) Anti-cd3 antibodies and methods of use thereof
EA041830B1 (ru) БИСПЕЦИФИЧЕСКОЕ АНТИТЕЛО, СВЯЗЫВАЮЩЕЕ ГЛИПИКАН 3 И CD3ε (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ ЕГО, И СПОСОБ ПОЛУЧЕНИЯ ЭТОГО АНТИТЕЛА

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40085531

Country of ref document: HK